Tag: Single tablet regimen

According to a 2024 study presented at the International AIDS Conference, a 2-drug regimen, Dovato, showed non-inferior efficacy to Biktarvy in maintaining viral suppression while showing significantly lower average weight gain for many patients. This highlights that when considering what is an alternative to Biktarvy, several effective options are available, catering to different patient needs and preferences.

First approved by the FDA in 2006, branded Atripla was discontinued by its manufacturer, Gilead Sciences, toward the end of 2021. The decision to remove the branded medication from the market was driven primarily by commercial factors and diminishing demand, not by concerns over its effectiveness or a sudden discovery of new safety issues.

First approved in 2006, Atripla was a revolutionary single-tablet regimen for HIV treatment, dramatically simplifying therapy for many patients. However, with over 15 years of new drug development in pharmacology since its introduction, a key question for many people with HIV is: is Atripla still recommended?.

Used by millions of people living with HIV, the medication Biktarvy has a key ingredient called bictegravir, which is often abbreviated as BIC. Understanding what drug is Bic requires looking at this powerful component and its role within the single-tablet regimen used to treat HIV-1 infection.

Since its FDA approval in 2018, Biktarvy has become a widely-used, powerful once-daily single-tablet regimen for treating HIV-1 infection. Many people wonder, 'what drugs are in Biktarvy?' and how this combination provides such effective viral suppression.